Abstract
Sumatriptan is the first selective serotonin (5-HT) agonist, which in numerous clinical trials proved to be a potent drug in the treatment of migraine and cluster headache and received approval for these indications in several countries. It is the first anti-migraine drug to act receptor-specific and has introduced a new era of headache treatment. Initially suspected as a potent anti-migraine drug because of its ability to constrict cerebral arteries, recent evidence indicates that its beneficial effects might be due to a blockade of neurotransmitter release and neurotransmission. Besides providing the physician with another helpful tool in the treatment of headache, sumatriptan provides further insight into the pathophysiology of headache. The article reviews the current knowledge of pharmacology, mechanism and clinical trials.
| Translated title of the contribution | Sumatriptan: Update information on pharmacology, mechanism of action and clinical use |
|---|---|
| Original language | German |
| Pages (from-to) | 31-39 |
| Number of pages | 9 |
| Journal | Aktuelle Neurologie |
| Volume | 22 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1995 |
| Externally published | Yes |